Key Points
- Edgewise CMO Joanne Donovan sold 28,662 shares on April 1 at an average price of $32.31, totaling $926,069.22, according to the SEC filing.
- The company reported Q4 EPS of ($0.47), missing estimates by $0.04, and analysts project a full-year EPS of -1.45, signaling continued unprofitability.
- Despite losses, the stock carries a consensus "Moderate Buy" rating with a $38.44 target, and several firms have higher targets (JPMorgan $45, Raymond James $46), while shares trade near their 1‑year high around $33.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 28,662 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $32.31, for a total value of $926,069.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Edgewise Therapeutics Price Performance
EWTX opened at $33.33 on Friday. The company has a market capitalization of $3.58 billion, a price-to-earnings ratio of -20.45 and a beta of 0.24. The firm's fifty day moving average price is $29.83 and its two-hundred day moving average price is $23.79. Edgewise Therapeutics, Inc. has a 1 year low of $10.60 and a 1 year high of $33.56.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). As a group, equities analysts anticipate that Edgewise Therapeutics, Inc. will post -1.45 EPS for the current year.
Analyst Ratings Changes
EWTX has been the subject of several analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Edgewise Therapeutics in a research note on Wednesday, January 21st. HC Wainwright upgraded Edgewise Therapeutics to a "strong-buy" rating in a report on Thursday, February 26th. Stifel Nicolaus set a $25.00 price objective on Edgewise Therapeutics in a research report on Thursday, February 26th. JPMorgan Chase & Co. upped their price objective on Edgewise Therapeutics from $34.00 to $45.00 and gave the company an "overweight" rating in a research note on Tuesday, March 17th. Finally, Raymond James Financial set a $46.00 target price on Edgewise Therapeutics in a research report on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $38.44.
Get Our Latest Report on EWTX
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of EWTX. Seven Fleet Capital Management LP bought a new stake in shares of Edgewise Therapeutics in the 4th quarter worth approximately $50,000. Jones Financial Companies Lllp purchased a new position in Edgewise Therapeutics in the first quarter valued at approximately $47,000. Bessemer Group Inc. grew its holdings in Edgewise Therapeutics by 1,170.3% during the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company's stock valued at $38,000 after purchasing an additional 2,165 shares during the period. Steward Partners Investment Advisory LLC grew its holdings in Edgewise Therapeutics by 23.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company's stock valued at $71,000 after purchasing an additional 550 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in Edgewise Therapeutics in the second quarter worth $45,000.
Edgewise Therapeutics Company Profile
(
Get Free Report)
Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.
At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
